Biomerica Inc SEC filings BMRA
Biomerica Inc has 605 filings in SEC EDGAR's recent list, going back to Sep 28, 1995. Its latest annual report, Form 10-K, was filed on Aug 31, 2026 for the period ended May 31, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 15, 2026, covering the quarter ended Aug 31, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (officer or director change). The company's fiscal year ends on May 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 16, 2026 | Oct 16, 2026 |
| DEFA14A | Additional proxy material | Oct 23, 2025 | — |
| DEF 14A | Proxy statement | Oct 20, 2025 | Dec 12, 2025 |
| PRE 14A | Preliminary proxy statement | Oct 9, 2025 | Oct 9, 2025 |
| DEF 14A | Proxy statement | Sep 30, 2024 | Sep 30, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 20, 2024 | Dec 13, 2024 |
| DEF 14A | Proxy statement | Sep 27, 2023 | Sep 27, 2023 |
| DEF 14A | Proxy statement | Sep 27, 2022 | Dec 7, 2022 |
| DEF 14A | Proxy statement | Sep 28, 2021 | Dec 9, 2021 |
| DEF 14A | Proxy statement | Sep 25, 2020 | Dec 10, 2020 |
| DEF 14A | Proxy statement | Sep 24, 2019 | Dec 11, 2019 |
| DEF 14A | Proxy statement | Sep 28, 2018 | Dec 12, 2018 |
| DEF 14A | Proxy statement | Sep 28, 2017 | Dec 13, 2017 |
| DEF 14A | Proxy statement | Sep 28, 2016 | Dec 14, 2016 |
| DEF 14A | Proxy statement | Sep 28, 2015 | Dec 16, 2015 |
| DEF 14A | Proxy statement | Sep 29, 2014 | Dec 15, 2014 |
| DEF 14A | Proxy statement | Sep 30, 2013 | Dec 11, 2013 |
| DEF 14A | Proxy statement | Sep 28, 2012 | Dec 11, 2012 |
| DEF 14A | Proxy statement | Sep 28, 2011 | Sep 28, 2011 |
| DEF 14A | Proxy statement | Sep 29, 2010 | Dec 15, 2010 |
| DEF 14A | Proxy statement | Sep 29, 2009 | Dec 10, 2009 |
| DEF 14A | Proxy statement | Sep 29, 2008 | Dec 3, 2008 |
| DEF 14A | Proxy statement | Sep 28, 2007 | Nov 29, 2007 |
| DEF 14A | Proxy statement | Sep 28, 2006 | Nov 29, 2006 |
| DEF 14A | Proxy statement | Sep 28, 2005 | Nov 22, 2005 |
| DEF 14A | Proxy statement | Sep 28, 2004 | Nov 19, 2004 |
| DEF 14A | Proxy statement | Sep 30, 2002 | Nov 20, 2002 |
| PRE 14A | Preliminary proxy statement | Sep 25, 2002 | Nov 20, 2002 |
| DEF 14A | Proxy statement | Oct 1, 2001 | Nov 13, 2001 |
| PRE 14A | Preliminary proxy statement | Sep 21, 2001 | Nov 13, 2001 |
| DEF 14A | Proxy statement | Oct 3, 2000 | Nov 13, 2000 |
| DEF 14A | Proxy statement | Sep 23, 1999 | Oct 25, 1999 |
| PRE 14A | Preliminary proxy statement | Sep 14, 1999 | Oct 25, 1999 |
| DEF 14A | Proxy statement | Sep 29, 1998 | Dec 7, 1998 |
| DEF 14A | Proxy statement | Sep 26, 1997 | Nov 10, 1997 |
| DEF 14A | Proxy statement | Sep 24, 1996 | Nov 12, 1996 |
| DEF 14A | Proxy statement | Sep 28, 1995 | Nov 9, 1995 |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- BMRA (Nasdaq)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 73290
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.